Zimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy in Patients With Untreated Metastatic Non-Small Cell Lung Cancer
NCT ID: NCT05502237
Last Updated: 2026-01-15
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE3
1069 participants
INTERVENTIONAL
2022-10-12
2029-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study Evaluating Effectiveness and Safety of Zimberelimab and Domvanalimab in Lung Cancer
NCT04736173
Study to Evaluate Monotherapy and Combination Immunotherapies in Participants With PD-L1 Positive Non-small Cell Lung Cancer
NCT04262856
Safety and Efficacy of Zimberelimab (AB122) in Combination With Domvanalimab (AB154) and Etrumadenant (AB928) in Patients With Previously Treated Non-Small Cell Lung Cancer
NCT04791839
Study of Novel Treatment Combinations in Patients With Lung Cancer
NCT05633667
A Study to Evaluate Immunotherapy Combinations in Participants With Lung Cancer
NCT03846310
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Zimberelimab (ZIM) +Domvanalimab (DOM) + Chemotherapy
Participants will receive ZIM 360 mg + DOM 1200 mg (up to 35 doses) with chemotherapy every 3 weeks (Q3W) on Day 1 of each 21-day cycle.
Choice of chemotherapy is dependent on histology.
* Participants with nonsquamous histology will receive cisplatin 75 mg/m\^2 or carboplatin area under the concentration versus time curve (AUC)5 + pemetrexed 500 mg/m\^2 Q3W for first 4 cycles. After the completion of the first 4 cycles, participants with nonsquamous histology may continue with maintenance pemetrexed 500 mg/m\^2 Q3W until disease progression or intolerable toxicities.
* Participants with squamous histology will receive carboplatin AUC 6 Q3W with paclitaxel 200 mg/m\^2 Q3W or nab-paclitaxel 100 mg/m\^2 weekly (QW) for first 4 cycles.
Zimberelimab
Administered intravenously
Domvanalimab
Administered intravenously
Carboplatin
Administered intravenously
Cisplatin
Administered intravenously
Paclitaxel
Administered intravenously
Nab-paclitaxel
Administered intravenously
Pemetrexed
Administered intravenously
Pembrolizumab (PEMBRO) + Chemotherapy
Participants will receive PEMBRO 200 mg (up to 35 doses) with chemotherapy Q3W on Day 1 of each 21-day cycle.
Choice of chemotherapy is dependent on histology.
* Participants with nonsquamous histology will receive cisplatin 75 mg/m\^2 or carboplatin AUC 5 + pemetrexed 500 mg/m\^2 Q3W for first 4 cycles. After the completion of the first 4 cycles, participants with nonsquamous histology may continue with maintenance pemetrexed 500 mg/m\^2 Q3W until disease progression or intolerable toxicities.
* Participants with squamous histology will receive carboplatin AUC 6 Q3W with paclitaxel 200 mg/m\^2 Q3W or nab-paclitaxel 100 mg/m\^2 weekly (QW) for first 4 cycles.
Pembrolizumab
Administered intravenously
Carboplatin
Administered intravenously
Cisplatin
Administered intravenously
Paclitaxel
Administered intravenously
Nab-paclitaxel
Administered intravenously
Pemetrexed
Administered intravenously
Zimberelimab (ZIM) + Chemotherapy
Participants will receive ZIM 360 mg (up to 35 doses) with chemotherapy Q3W on Day 1 of each 21-day cycle.
Choice of chemotherapy is dependent on histology.
* Participants with nonsquamous histology will receive cisplatin 75 mg/m\^2 or carboplatin AUC 5 + pemetrexed 500 mg/m\^2 Q3W for first 4 cycles After the completion of the first 4 cycles, participants with nonsquamous histology may continue with maintenance pemetrexed 500 mg/m\^2 Q3W until disease progression or intolerable toxicities.
* Participants with squamous histology will receive carboplatin AUC 6 Q3W with paclitaxel 200 mg/m\^2 Q3W or nab-paclitaxel 100 mg/m\^2 weekly (QW) for first 4 cycles.
Zimberelimab
Administered intravenously
Carboplatin
Administered intravenously
Cisplatin
Administered intravenously
Paclitaxel
Administered intravenously
Nab-paclitaxel
Administered intravenously
Pemetrexed
Administered intravenously
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Zimberelimab
Administered intravenously
Domvanalimab
Administered intravenously
Pembrolizumab
Administered intravenously
Carboplatin
Administered intravenously
Cisplatin
Administered intravenously
Paclitaxel
Administered intravenously
Nab-paclitaxel
Administered intravenously
Pemetrexed
Administered intravenously
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Pathologically documented NSCLC that meets both of the criteria below:
* Have documented evidence of Stage IV NSCLC disease at the time of enrollment (based on American Joint Committee on Cancer (AJCC), Eighth Edition).
* Have documented negative test results for epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) mutations.
* Have no actionable genomic alterations such as ROS proto-oncogene 1 (ROS1), neurotrophic tyrosine receptor kinase (NTRK), proto-oncogene B-raf (BRAF), RET mutations, or other driver oncogenes with approved frontline therapies.
* Have not received prior systemic treatment for metastatic NSCLC.
* Measurable disease per RECIST v1.1 criteria by investigator assessment.
* Eastern Cooperative Oncology Group performance status (ECOG PS) score of 0 or 1.
* Have adequate organ functions.
Exclusion Criteria
* Positive serum pregnancy test or individuals who are breastfeeding or have plans to breastfeed during the study period.
* Received prior treatment with any anti-PD-1, anti-PD-L1, or any other antibody targeting an immune checkpoint.
* Known hypersensitivity to the study drug, its metabolites, or formulation excipient.
* Have an active second malignancy or have had an active second malignancy within 3 years prior to enrollment.
* Have an active autoimmune disease that required systemic treatment in past 2 years (i.e., with use of disease-modifying agents, corticosteroids, or immunosuppressive drugs).
* Are receiving chronic systemic steroids.
* Have significant third-space fluid retention.
* Have untreated central nervous system (CNS) metastases and/or carcinomatous meningitis.
* Active chronic inflammatory bowel disease (ulcerative colitis, Crohn's disease) or gastrointestinal perforation within 6 months of enrollment.
* Has a history of (noninfectious) pneumonitis/interstitial lung disease that required steroids or has current pneumonitis/interstitial lung disease.
* Has had an allogenic tissue/solid organ transplant.
* Have received a live-virus vaccination within 30 days of planned treatment start. Seasonal flu and COVID-19 vaccines that do not contain live virus are permitted.
* Have known active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Arcus Biosciences, Inc.
INDUSTRY
Gilead Sciences
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Gilead Study Director
Role: STUDY_DIRECTOR
Gilead Sciences
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Palo Verde Hematology Oncology Ltd
Glendale, Arizona, United States
California Cancer Associates for Research and Excellence
San Marcos, California, United States
Texas Oncology
Santa Barbara, California, United States
Innovative Clinical Research Institute
Whittier, California, United States
Eastern CT Hematology and Oncology Associates
Norwich, Connecticut, United States
George Washington Medical Faculty Associates
Washington D.C., District of Columbia, United States
Lake City Cancer Care
Lake City, Florida, United States
Florida Cancer Specialists
Sarasota, Florida, United States
Moffitt Cancer Center
Tampa, Florida, United States
Peachtree Hematology Oncology Consultants
Atlanta, Georgia, United States
Illinois Cancer Care
Peoria, Illinois, United States
Messino Cancer Centers
Asheville, North Carolina, United States
Oncology Hematology Care, Inc.
Cincinnati, Ohio, United States
Hematology & Oncology Associates
Eugene, Oregon, United States
AHN Allegheny General Hospital
Pittsburgh, Pennsylvania, United States
Arlington Cancer Center
Arlington, Texas, United States
Texas Oncology - Austin
Austin, Texas, United States
Texas Oncology
Dallas, Texas, United States
Texas Oncology- Denison
Sherman, Texas, United States
US Oncology Investigational Products Center (IPC)
Arlington, Virginia, United States
Oncology and Hematology Associates of Southwest Virginia, Inc
Blacksburg, Virginia, United States
Northwest Cancer Specialists, PC
Vancouver, Washington, United States
Investigaciones CORI S.R.L.
Capital, , Argentina
Centro Médico Privado Centro de Especialidades Médicas Ambulatorias e Investigación Clínica
Cardoba, , Argentina
Centro Medico Barrio Parque
Ciudad Autanoma Buenos Aires, , Argentina
Sanatorio Allende
Córdoba, , Argentina
Sanatorio Britanico de Rosario
Rosario, , Argentina
Sanatorio Parque de Rosario
Rosario, , Argentina
Hospital Provincial del Centenario
Rosario, , Argentina
Instituto Medico de la Fundacion Estudios Clinicos
Rosario, , Argentina
CAIPO - Centro para la Atención Integral del Paciente Oncológico
San Miguel de Tucumán, , Argentina
Clínica Viedma
Viedma, , Argentina
Klinikum Klagenfurt am Woerthersee
Klagenfurt, , Austria
Ordensklinikum Linz GmbH, Elisabethinen
Linz, , Austria
Krankenhaus Nord - Klinik Floridsdorf
Vienna, , Austria
Klinikum Wels-Grieskirchen
Wels, , Austria
Algemeen Ziekenhuis Sint-Lucas
Aalst, , Belgium
Grand Hopital de Charleroi asbl (GHdC)
Charleroi, , Belgium
AZ Sint-Maarten
Mechelen, , Belgium
CHU UCL Namur / Site Sainte Elisabeth
Namur, , Belgium
Cenantron Centro Avançado de Tratamento Oncologico Ltda
Belo Horizonte, , Brazil
Hospital Evangelico de Cachoeiro de Itapemirim
Cachoeiro de Itapemirim, , Brazil
Fundacao Universidade De Caxias Do Sul - FUCS/RS
Caxias do Sul, , Brazil
Instituto do Câncer do Ceará - ICC
Fortaleza, , Brazil
Oncosite - Centro de Pesquisa Clinica em Oncologia LTDA
Ijuí, , Brazil
Irmandade da Santa Casa de Misericordia de Porto Alegre
Porto Alegre, , Brazil
Hospital de Clínicas de Porto Alegre
Porto Alegre, , Brazil
Hospital São Lucas da PUCRS
Porto Alegre, , Brazil
Hospital Ana Nery Santa Cruz do Sul
Santa Cruz do Sul, , Brazil
Instituto Brasiliero de Controle do Cancer IBCC
São Paulo, , Brazil
Centro Des Pesquisas Clinicas da Fundacao Doutor Amaral Carvalho
São Paulo, , Brazil
Centre Integre de sante et de services sociaux de la Monteregie Centre
Greenfield Park, , Canada
Moncton Hospital
Moncton, , Canada
CISSS des Laurentides
Québec, , Canada
Centre de santé et services sociaux de Rimouski-Neigette
Rimouski, , Canada
BC Cancer - Victoria
Victoria, , Canada
Clinica Alemana de Santiago
Las Condes, , Chile
Clinica Puerto Montt
Port Montt, , Chile
Orlandioncologia
Providencia, , Chile
Oncovida- Santiago
Providencia, , Chile
Biocinetic
Santiago, , Chile
James Lind Centro de Investigacion del Cancer
Temuco, , Chile
Oncocentro APYS
Viña del Mar, , Chile
West China Hospital Sichuan University
Chengdu, , China
Chongqing University Cancer Hospital
Chongqing, , China
Deyang People's Hospital
Deyang, , China
Fujian Cancer Hospital
Fuzhou, , China
The First Affiliated Hospital of Guangzhou Medical University
Guangzhou, , China
Guangzhou First People's Hospital
Guangzhou, , China
Nanfang Hospital, Southern Medical University
Guangzhou, , China
Zhejiang Cancer Hospital
Hangzhou, , China
Anhui Chest Hospital
Hefei, , China
The Second Affiliated Hospital of Nanchang University
Jiangxi, , China
Shandong Cancer Hospital
Jinan, , China
Jiangxi Chest Hospital
Nanchang, , China
Nanjing Drum Tower Hospital
Nanjing, , China
Guangxi Medical University Cancer Hospital
Nanning, , China
Shanghai Chest Hospital
Shanghai, , China
Shanghai East Hospital
Shanghai, , China
Shanghai Pulmonary Hospital
Shanghai, , China
Cancer Hospital of Shantou University Medical College
Shantou, , China
Tianjin Medical University Cancer Institute & Hospital
Tianjin, , China
Union Hospital Tongji Medical College Huazhong University of Science and Technology
Wuhan, , China
Tongji Hospital Tongji Medical College of Hust
Wuhan, , China
The First Affiliated Hospital of Xian Jiaotong University
Xi'an, , China
The First Affiliated Hospital of Xinxiang Medical College
Xinxiang, , China
Henan Cancer Hospital
Zhengzhou, , China
Ambroise-Pare Hospital, Assistance Publique - Hopitaux de Paris
Boulogne-Billancourt, , France
CHU de Caen
Caen, , France
Clinique Victor Hugo, Centre de Cancerologie de la Sarthe
Le Mans, , France
Hopital Nord
Marseille, , France
Institut de Cancer de Montpellier (ICM) - Val d'Aurelle
Montpellier, , France
Centre Antoine Lacassagne
Nice, , France
Institut de cancerologie de l'ouest (ICO)
Saint-Herblain, , France
Hopital d'Instruction des Armees (HIA) Begin
Saint-Mandé, , France
Centre Hospitalier de Saint-Quentin
Saint-Quentin, , France
Institut de Cancerologie Strasbourg Europe (ICANS)
Strasbourg, , France
Hôpital Foch
Suresnes, , France
CHI de Toulon la Seyne-sur-Mer Hopital Sainte Musse
Toulon, , France
Augusta-Kranken-Anstalt gGmbh Klinik für Hämatologie Onkologie und Palliativmedizin
Bochum, , Germany
Klinikum Chemnitz gGmbH
Chemnitz, , Germany
Kliniken der Stadt Köln ggmbh, Krankenhaus Koln-Merheim/Lungenklinik
Cologne, , Germany
Universitatsklinikum Essen / Westdeutsches Tumorzentrum, Innere Klinik (Tumorforschung)
Essen, , Germany
Universitätsklinikum Freiburg, Klinik für Innere Medizin I Hämatologie, Onkologie und Stammzelltransplantation
Freiburg im Breisgau, , Germany
LungenClinic Grosshansdorf
Großhansdorf, , Germany
Krankenhaus Martha-Maria Halle Dölau
Halle, , Germany
Asklepios Kliniken Hamburg
Hamburg, , Germany
Katholisches Marienkrankenhaus gGmbH
Hamburg, , Germany
Lungenklinik Hemer, Zentrum fur Pneumologie and Thoraxchirurgie
Hemer, , Germany
Vincentius-Diakonissen-Kliniken gAG, St. Vincentius-Kliniken, Medizinische Klinik 2
Karlsruhe, , Germany
Klinikum Kassel
Kassel, , Germany
Universitatsklinikum Schleswig-Holstein
Lübeck, , Germany
Johannes Wesling Klinikum Minden
Minden, , Germany
Munchen Klinik Bogenhausen, Klinik fur Pneumologie und Pneumologische Onkologie
München, , Germany
Sana Klinikum Offenbach GmbH, Medizinische Klinik IV, Hämatologie und Internistische Onkologie
Offenbach, , Germany
Queen Elizabeth Hospital
Hong Kong, , Hong Kong
Queen Mary Hospital
Hong Kong, , Hong Kong
Prince of Wales Hospital
New Territories, , Hong Kong
Soroka University Medical Center, Itzchak Rager Blvd.
Beersheba, , Israel
Shaare Zedek Medical Center
Jerusalem, , Israel
Oncology Institute, Galilee Medical Center, Route 89 Nahariya-Cabri
Nahariya, , Israel
Rabin Medical Center
Petah Tikva, , Israel
Kaplan Medical Center
Rehovot, , Israel
Tel-Aviv Sourasky Medical Center
Tel Aviv, , Israel
Azienda Ospedaliera San Giuseppe Moscati
Avellino, , Italy
IRCCS Fondazoine del Piemonte per l'Oncologia
Candiolo, , Italy
Azienda Socio Sanitaria Territoriale di Cremona
Cremona, , Italy
Ospedale Policlinico San Martino
Genova, , Italy
Ospedale San Raffaele
Milan, , Italy
Azienda Ospedaliero Universitaria di Modena
Modena, , Italy
AORN Cardarelli
Naples, , Italy
Azienda Ospedaliera dei Colli
Napoli, , Italy
IRCCS Policlinico S. Matteo, Dipartimento Oncologia Ematologia-Oncologia Medica
Pavia, , Italy
Azienda Sanitaria Territoriale Pesaro e Urbino (AST)
Pesaro, , Italy
Ospedale Guglielmo da Saliceto AUSL di Piacenza
Piacenza, , Italy
Centro di Riferimento Oncologico
Pordenone, , Italy
Regina Elena Institute for Cancer Research
Rome, , Italy
ASST Bergamo Ovest- ospedale di Treviglio
Treviglio, , Italy
National Cancer Center Hospital East
Chiba, , Japan
National Hospital Organization Shikoku Cancer Center
Ehime, , Japan
Kyushu University Hospital
Fukuoka, , Japan
Kurume University Hospital
Fukuoka, , Japan
National Hospital Organization Himeji Medical Center
Hyōgo, , Japan
Hyogo Cancer Center
Hyōgo, , Japan
Kanazawa University Hospital
Ishikawa, , Japan
Kanagawa Cancer Center
Kanagawa, , Japan
Sendai Kousei Hospital
Miyagi, , Japan
Niigata Cancer Center Hospital
Niigata, , Japan
Osaka Metropolitan University Hospital
Osaka, , Japan
Osaka Medical and Pharmaceutical University Hospital
Osaka, , Japan
Kindai University Hospital
Osaka, , Japan
National Hospital Organization Kinki Chuo Chest Medical Center
Osaka, , Japan
Saitama Medical University
Saitama, , Japan
Health Pharma Professional Research S.A. de C.V.
México, , Mexico
Hospital Universitario Dr. Jose Eleuterio Gonzalez
Mitras Centro, , Mexico
Oaxaca Site Management Organization
Oaxaca City, , Mexico
Centro de Investigacion Clinica de Oaxaca
Oaxaca City, , Mexico
Clinical Medical Research SC.
Orizaba Centro, , Mexico
Clinica Integral Internacional de Oncologia S de RL de CV
Puebla City, , Mexico
FAICIC Clínical Research
Veracruz, , Mexico
Amphia Ziekenhuis
Breda, , Netherlands
Ziekenhuis Gelderse Vallei
Ede, , Netherlands
Universitair Medisch Centrum Groningen
Groningen, , Netherlands
Ziekenhuis St Jansdal
Harderwijk, , Netherlands
TweeSteden Ziekenhuis
Tilburg, , Netherlands
Hospital Prof. Doutor Fernando Fonseca
Amadora, , Portugal
Instituto Português de Oncologia de Lisboa Francisco Gentil
Lisbon, , Portugal
Fundacao Champalimaud
Lisbon, , Portugal
Hospital Beatriz Angelo. Hospital de Loures.
Lisbon, , Portugal
Centro Hospitalar Universitário Lisboa Norte - Hospital Pulido Valente
Lisbon, , Portugal
Centro Hospitalar Universitario Sao Joao, EPE
Porto, , Portugal
Unidade Local de Saude de Matosinhos EPE - Hospital Pedro Hispano SA
Senhora da Hora, , Portugal
Raffles Hospital
Singapore, , Singapore
Tang Tock Seng Hospital
Singapore, , Singapore
SMG - SNU Boramae Medical Center
Dongjak-Gu, , South Korea
Samsung Medical Center
Gangnam-Gu, , South Korea
National Cancer Center
Goyang, , South Korea
Chungbuk National University Hospital
Heungdeok-Gu, , South Korea
Inha University Hospital
Incheon, , South Korea
Gachon University Gil Medical Center
Inchon, , South Korea
Kosin University Gospel Hospital
Seogu, , South Korea
Severance Hospital, Yonsei University Health System
Seoul, , South Korea
Asan Medical Center
Seoul, , South Korea
The Catholic University of Korea, Seoul St. Mary's Hospital
Seoul, , South Korea
The Catholic University of Korea, Saint Vincent's Hospital
Suwon, , South Korea
Ajou University Hospital
Suwon, , South Korea
Hospital Clinic de Barcelona
Barcelona, , Spain
Hospital de la Santa Creu i de Sant Pau
Barcelona, , Spain
Hospital Universitari Dexeus (USP Institut Universitari Dexeus/Hospital Universitari Quiron Dexeus)
Barcelona, , Spain
Hospital Universitari Vall D'Hebron
Barcelona, , Spain
Hospital Parc Tauli
Barcelona, , Spain
Hospital Universitario Reina Sofia
Córdoba, , Spain
Hospital Doctor Josep Trueta
Girona, , Spain
Hospital Universitario de Jaen
Jaén, , Spain
Hospital Universitario de Canarias
Las Palmas de Gran Canaria, , Spain
Hospital Universitario Fundacion Jimenez Diaz
Madrid, , Spain
Clinica Universidad de Navarra
Madrid, , Spain
Hospital Universitario La Paz
Madrid, , Spain
Hospital Universitario Puerta de Hierro de Majadahonda
Majadahonda, , Spain
Hospital Sant Joan de Reus
Reus, , Spain
Hospital Regional Universitario de Malaga
Rincón de la Victoria, , Spain
Hospital Universitario Virgen Macarena
Seville, , Spain
Hospital Universitario Virgen del Rocio
Seville, , Spain
Instituto Valenciano De Oncologia (IVO)
Valencia, , Spain
Hospital Universitari i Politecnic La Fe
Valencia, , Spain
Hospital Vithas Valencia 9 de Octubre
Valencia, , Spain
Changhua Christian Hospital
Changhua, , Taiwan
Kaohsiung Medical University Chung-Ho Memorial Hospital
Kaohsiung City, , Taiwan
E-DA Hospital
Kaohsiung City, , Taiwan
Chang Gung Memorial Hospital Kaohsiung
Kaohsiung City, , Taiwan
National Cheng Kung University Hospital
Tainan, , Taiwan
Chi Mei Hospital, Liouying
Tainan, , Taiwan
Taipei Veterans General Hospital
Taipei, , Taiwan
National Taiwan University Hospital
Taipei, , Taiwan
Chang Gung Memorial Hospital Linkou Branch of the Chang Gung Medical Foundation
Taoyuan, , Taiwan
Ankara Bilkent Sehir Hastanesi
Ankara, , Turkey (Türkiye)
Dr. Abdurrahman Yurtaslan Ankara Onkoloji Egitim ve Arastirma Hastanesi
Ankara, , Turkey (Türkiye)
Trakya University Faculty of Medicine
Edirne, , Turkey (Türkiye)
Istanbul University Cerrahpasa Medical Faculty Hospital
Fatih, , Turkey (Türkiye)
Goztepe Prof. Dr. Suleyman Yalcın Sehir Hastanesi
Istanbul, , Turkey (Türkiye)
Medipol Mega University Hospital
Istanbul, , Turkey (Türkiye)
Acibadem Mehmet Ali Aydinlar Universitesi Atakent Hastanesi
Kaakaekmece, , Turkey (Türkiye)
Turgut Ozal Medical Faculty
Malatya, , Turkey (Türkiye)
Colchester General Hospital
Colchester, , United Kingdom
St Bartholomew's Hospital, Barts Health NHS Trust
London, , United Kingdom
The Christie NHS Foundation Trust, Department of Medical Oncology
Manchester, , United Kingdom
University Hospital Southampton Nhs Foundation Trust
Southampton, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Related Links
Access external resources that provide additional context or updates about the study.
Gilead Clinical Trials Website
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2022-000578-25
Identifier Type: EUDRACT_NUMBER
Identifier Source: secondary_id
GS-US-626-6216
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.